Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

NCT04561362 2025-11-14

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Phase 1/2 Active not recruiting

329 enrolled

BreastGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Renal Insufficiency, Triple Negative Breast Neoplasms

NCT05565417 2025-10-16

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Phase 1/2 Active not recruiting

67 enrolled

BreastGastrointestinalHead & NeckLymphoidThoracic

Squamous Cell Carcinoma of Head and Neck, Burkitt Lymphoma, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Hodgkin Disease, Lymphoma, Lymphoma, Follicular, Colorectal Neoplasms, Lymphoma, Large B-Cell, Diffuse, Triple Negative Breast Neoplasms

NCT02393794 2025-10-06

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1/2 Active not recruiting

51 enrolled

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT05057013 2025-08-11

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Phase 1/2 Active not recruiting

81 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Lethal Congenital Contracture Syndrome 2, Fibromatosis, Gingival, 2, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Prostatic Neoplasms, Castration-Resistant, Triple Negative Breast Neoplasms

NCT05888831 2025-06-11

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Phase 1/2 Active not recruiting

100 enrolled

BreastThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Triple Negative Breast Neoplasms

NCT04331067 2025-04-23

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

Phase 1/2 Active not recruiting

15 enrolled 12 charts

Breast

Triple Negative Breast Neoplasms

NCT05101096 2025-03-25

ASCENT-J02

Phase 1/2 Active not recruiting

135 enrolled

Breast

Triple Negative Breast Neoplasms

NCT02734290 2025-03-10

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

Phase 1/2 Active not recruiting

29 enrolled 12 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03616886 2024-12-19

SYNERGY

Phase 1/2 Active not recruiting

129 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT05620134 2024-10-15

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Phase 1/2 Active not recruiting

263 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Neoplasms, Thyroid Neoplasms, Colorectal Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03911973 2024-06-07

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers

Phase 1/2 Active not recruiting

37 enrolled

Breast

Triple Negative Breast Neoplasms

Clinical Trials

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

TRIFOUR

A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Onvansertib + Paclitaxel In TNBC

BEGONIA

ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC

Ribociclib and Bicalutamide in AR+ TNBC

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors

Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer

ASCENT-J02

Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer

SYNERGY

Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer

Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers